- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Redwood City Today
By the People, for the People
HC Wainwright Reaffirms Neutral Rating for Soleno Therapeutics
Analysts lower price target on biotech stock amid market shifts
Apr. 8, 2026 at 12:07pm
Got story updates? Submit your updates here. ›
HC Wainwright, a leading investment bank, has reaffirmed its 'neutral' rating on shares of Soleno Therapeutics (NASDAQ:SLNO), a biopharmaceutical company focused on rare and orphan diseases. The analysts have lowered their price target on the stock from $100 to $53, citing market changes and a shift in their outlook.
Why it matters
Soleno Therapeutics is a key player in the rare disease treatment space, with its lead candidate DCCR being investigated for the treatment of Prader-Willi syndrome. The company's stock performance and analyst ratings can have a significant impact on investor sentiment and the company's ability to secure funding for further research and development.
The details
In their research note, the HC Wainwright analysts cited several factors contributing to the lowered price target, including a shift in the overall market landscape and a reassessment of the company's pipeline and commercial prospects. The analysts maintained their 'neutral' rating, suggesting that while they see potential in Soleno's approach, there are also risks and uncertainties that warrant a cautious stance.
- The research note was released on Wednesday, April 8, 2026.
The players
HC Wainwright
A leading investment bank that provides research coverage and investment banking services to publicly traded companies.
Soleno Therapeutics
A clinical-stage biopharmaceutical company focused on developing therapies for rare and orphan diseases, including Prader-Willi syndrome.
What’s next
Investors will be closely watching Soleno Therapeutics' upcoming financial results and any updates on the development of its lead candidate DCCR for Prader-Willi syndrome. The company's ability to navigate the changing market landscape and address analyst concerns will be crucial in determining the stock's future performance.
The takeaway
The revised rating and price target from HC Wainwright reflect the volatility and uncertainty in the biotech sector, particularly for companies focused on rare and orphan diseases. Soleno Therapeutics will need to demonstrate clear progress in its clinical trials and commercial strategy to regain investor confidence and secure the necessary funding to advance its pipeline.
